Back to discover
Disease

Renal Insufficiency, Chronic

Late-stage therapeutic developmentActively researchedRising momentum
72
Publications
16
Clinical trials
12
Related conditions
2
Related treatments
1
Related proteins
2025
Latest publication
Current focus
Therapeutic developmentInflammation & immunityMetabolic & lifestyle factorsDisease mechanisms & pathology
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 2 clinical trials expected to report results, the earliest in Q2 2027.
  • Active recent publication activity.
Major developments
Upcoming trial readoutImportant
Results expected Q2 20272026-05-18
Upcoming trial readoutImportant
Results expected Q3 20292026-06-09

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Epoetin zetaapproved

Approval — Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and… (2007)

Approval — Infants, children and adolescents Growth disturbance due to insufficient secretion of gr… (2006)

Research-associated treatments

Clinical trials

15 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
16
All trials
4
Active
9
Late-stage
5
Completed
Late-stage studies
Recently completed

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2007emaApprovalEpoetin zeta· Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients: treatment of anaemia associated with chronic renal failure in adult and paediatric patients on haemodialysis and adult patients on peritoneal dialysis; treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. Treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy). Retacrit can be used to increase the yield of autologous blood from patients in a predonation programme. Its use in this indication must be balanced against the reported risk of thromboembolic events. Treatment should only be given to patients with moderate anaemia (no iron deficiency), if blood-saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (four or more units of blood for females or five or more units for males). Retacrit can be used to reduce exposure to allogeneic blood transfusions in adult non-iron-deficient patients prior to major elective orthopaedic surgery, having a high perceived risk for transfusion complications. Use should be restricted to patients with moderate anaemia (e.g. Hb 10-13 g/dl) who do not have an autologous predonation programme available and with expected moderate blood loss (900 to 1800 ml). source ↗
2006emaApprovalGrowth Hormone· Infants, children and adolescents Growth disturbance due to insufficient secretion of growth hormone (GH). Growth disturbance associated with Turner syndrome. Growth disturbance associated with chronic renal insufficiency. Growth disturbance (current height standard-deviation score (SDS) < -2.5 and parental adjusted SDS < -1) in short children / adolescents born small for gestational age (SGA), with a birth weight and / or length below -2 standard deviations (SDs), who failed to show catch-up growth (height velocity (HV) SDS < 0 during the last year) by four years of age or later. Prader-Willi syndrome (PWS), for improvement of growth and body composition. The diagnosis of PWS should be confirmed by appropriate genetic testing. Adults Replacement therapy in adults with pronounced growth hormone deficiency. Patients with severe growth hormone deficiency in adulthood are defined as patients with known hypothalamic pituitary pathology and at least one known deficiency of a pituitary hormone not being prolactin. These patients should undergo a single dynamic test in order to diagnose or exclude a growth hormone deficiency. In patients with childhood-onset isolated GH deficiency (no evidence of hypothalamic-pituitary disease or cranial irradiation), two dynamic tests should be recommended, except for those having low insulin-like-growth-factor-I (IGF-I) concentrations (SDS < -2) who may be considered for one test. The cut-off point of the dynamic test should be strict. source ↗
2001emaApprovalGrowth Hormone· Long-term treatment of children with growth failure due to inadequate endogenous growth hormone secretion. Long-term treatment of growth failure associated with Turner syndrome. Treatment of prepubertal children with growth failure associated with chronic renal insufficiency up to the time of renal transplantation. Replacement of endogenous growth hormone in adults with growth hormone deficiency of either childhood or adult-onset etiology. Growth hormone deficiency should be confirmed appropriately prior to treatment. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

72 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20082025
Most influential
Recent publications
Major themes8
  • Renal Insufficiency, Chronic37
  • Cardiovascular Diseases12
  • Diabetes Mellitus, Type 211
  • Gastrointestinal Microbiome6
  • Diabetes Mellitus5
  • Sodium-Glucose Transporter 2 Inhibitors5
  • Heart Failure4
  • Acute Kidney Injury3
Leading journals6
  • Nature reviews. Nephrology7
  • Kidney international5
  • Circulation3
  • Frontiers in immunology3
  • International journal of molecular sciences3
  • Nature reviews. Disease primers3
Leading researchers8
  • Rossing P7
  • Heerspink HJL5
  • Anker SD4
  • Claggett BL4
  • Perkovic V4
  • Solomon SD4
  • Tonelli M4
  • Vaduganathan M4
Affiliations (unnormalised)6
  • Brigham and Women's Hospital5
  • University of Texas Southwestern Medical Center4
  • Department of Clinical Medicine3
  • Department of Clinical Pharmacy and Pharmacology3
  • Ghent University Hospital3
  • Steno Diabetes Center Copenhagen3

Disease biology

1 match

Key proteins & gene products studied in this disease. Number shows shared papers.

Related conditions

12 matches

Diseases frequently studied alongside this one. Number shows shared papers.

Disease profile

A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.

Overview

Chronic renal insufficiency is a condition in which the kidneys function below normal for more than three months. It is staged by the degree of decline in glomerular filtration rate and by kidney damage such as proteinuria, with end-stage renal disease representing the most severe form.

Causes

The supplied grounding does not identify a single cause for chronic renal insufficiency. It is described as a chronic disease state that can arise in the context of diabetes, hypertension, ageing-related nephron loss, or as a continuum following acute kidney injury.

Pathophysiology

The disease is characterized by persistent reduction in kidney function, reflected by declining glomerular filtration rate and kidney damage such as proteinuria. The literature grounding also links chronic kidney disease to irreversible loss of kidney cells and nephrons, and to broader physiopathologic processes involving oxidative stress, immunity, cytokines, and the gastrointestinal microbiome.

Risk factors

Diabetes, hypertension, and ageing-related nephron loss are identified in the grounding as contributors to chronic kidney disease. The literature also notes that chronic kidney disease is an independent risk factor for cardiovascular disease and is associated with increased cardiovascular morbidity, premature mortality, and reduced quality of life.

Current standard of care

Management is described at the level of broad therapeutic classes and supportive measures rather than specific regimens. The grounding supports blood glucose control, blood pressure control, blockade of the renin-angiotensin-aldosterone system, and use of SGLT2 inhibitors in patients with type 2 diabetes; it also includes finerenone and semaglutide among co-studied therapies, along with diet, exercise, and synbiotics.

AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.